BrainsWay (NASDAQ:BWAY – Get Free Report) is expected to release its earnings data before the market opens on Tuesday, March 11th. Analysts expect BrainsWay to post earnings of $0.03 per share and revenue of $10.89 million for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.
BrainsWay Stock Up 2.6 %
NASDAQ BWAY opened at $9.41 on Friday. The firm has a market capitalization of $177.16 million, a P/E ratio of 94.11 and a beta of 1.29. BrainsWay has a 52 week low of $4.61 and a 52 week high of $11.79. The company has a 50-day moving average price of $10.21 and a 200-day moving average price of $9.55.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of BrainsWay in a research report on Monday, December 23rd.
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Read More
- Five stocks we like better than BrainsWay
- What is the NASDAQ Stock Exchange?
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Stocks to Buy While Others Stay on the Sidelines
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.
